NCT01002079View on ClinicalTrials.gov

Drug-Drug Interaction Study With Rifampin

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Alzheimer Disease
Interventions
DRUG

BMS-708163

Capsule, Oral, 125 mg, Once daily, 1 day

DRUG

Rifampin

Capsule, Oral, 600 mg, Once daily, 7 days

DRUG

Rifampin

Capsule, Oral, 600 mg, Once daily, 6 days

Trial Locations (1)

560100

Local Institution, Bangalore

Sponsors

Collaborators (1)

PRA Health Sciences
All Listed Sponsors
collaborator

PRA Health Sciences

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY